Anticancer drugs: Flipping the switch for selective GSK3 inhibition

Nature Reviews Drug Discovery 17, 314 (2018). doi:10.1038/nrd.2018.63 Author: Katie Kingwell Glycogen synthase kinase 3 (GSK3) is a potential therapeutic target in many diseases, including cancer and neurological disorders. But clinical trials of dual GSK3α/β inhibitors have not proved successful, and there is concern about on-target liabilities related to β-catenin signalling. Now, Wagner, Stegmaier and colleagues
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: Research Highlight Source Type: research